Ribavirin is indicated in combination with other medicinal products except peginterferon alfa-2a and peginterferon alfa-2b, for the treatment of chronic hepatitis C
Boehringer Ingelheim has filed for EU marketing approval of BI 201335 (faldaprevir) in combination with pegylated interferon and ribavirin (PegIFN/RBV)...
Background: The once-daily, ribavirin-free, pangenotypic, direct-acting antiviral regimen, glecaprevir coformulated with pibrentasvir, has shown high rates of sustained virological response in phase 2 and 3 studies.
Ribavirin is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1). Ribavirin is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).